Asthma and COPD Drugs Market is expected to reach US$ 82.2 Billion by 2036, driven by Advancements in Drug Discovery and ...
The first COPD patient has been dosed in a Phase 1b COPD trial testing Bambusa Therapeutics’ dual-target therapy BBT002.
The COPD therapeutics market presents opportunities in integrated care and digital advancements. Rising disease prevalence ...
Delaware-based AirNexis will develop, produce, and commercialize HSK39004, a dual inhibitor that can improve airflow ...
GSK has high hopes for Nucala thanks to its less frequent dosing – once a month, versus every other week for Dupixent – and ...
David Mannino is co-founder and chief medical officer of the COPD Foundation. He's an internal medicine doctor with a specialty in pulmonary, critical care, and sleep medicine at University of ...
Recent research suggests that certain biologic medications called monoclonal antibodies may help treat emphysema more effectively than some current therapies. These medications include benralizumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback